羟基脲治疗的镰状细胞贫血儿童及青少年血浆代谢组学
该研究采用多平台代谢组学方法,分析接受与未接受羟基脲治疗的镰状细胞贫血(SCA)儿童及青少年以及非SCA个体的血浆样本。
要点
- 羟基脲治疗可使SCA患者部分代谢物恢复至对照水平。
- 羟基脲治疗下肌酸/肌酐水平升高,提示精氨酸池和NO合成可能增加。
- 代谢组学结果扩展了SCA病理生理模型,涉及Lands循环受损和S1P合成增加。
核心结论
- 羟基脲治疗对SCA儿童及青少年代谢组有明显影响,可使特定代谢物恢复至对照水平。
研究设计与样本
- 研究采用多平台代谢组学方法,分析接受与未接受羟基脲治疗的SCA儿童及青少年以及非SCA个体的血浆样本。
主要发现
- PLS-DA分析可清晰区分不同研究组,揭示羟基脲治疗的明显代谢效应。
- 羟基脲治疗下肌酸/肌酐水平升高,提示精氨酸池和NO合成可能增加。
- 代谢组学结果扩展了SCA病理生理模型,包括Lands循环受损和1-磷酸鞘氨醇合成增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sickle cell anaemia (SCA) is a debilitating genetic haemoglobinopathy predominantly affecting the disenfranchised strata of society in Africa and the Americas. The most common pharmacological treatment for this disease is the administration of hydroxycarbamide (HC) for which questions remain regarding its mechanism of action, efficacy and long-term toxicity specifically in paediatric individuals. A multiplatform metabolomics approach was used to assess the metabolome of plasma samples from a population of children and adolescents with SCA with and without HC treatment along with non-SCA individuals. Fifty-three metabolites were identified by ultra-high performance liquid chromatography coupled to high-resolution mass spectrometry (UHPLC-HRMS) and 1 H nuclear magnetic resonance (NMR) with a predominance of membrane lipids, amino acids and organic acids. The partial least-squares discriminant analysis (PLS-DA) analysis allowed a clear discrimination between the different studied groups, revealing clear effects of the HC treatment in the patients' metabolome including rescue of specific metabolites to control levels. Increased creatine/creatinine levels under HC treatment suggests a possible increase in the arginine pool and increased NO synthesis, supporting existing models for HC action in SCA. The metabolomics results extend the current knowledge on the models for SCA pathophysiology including impairment of Lands' cycle and increased synthesis of sphingosine 1-phosphate. Putative novel biomarkers are suggested.
引用
- Ribeiro PR, Teixeira RDS, Souza AR, et al. Blood plasma metabolomics of children and adolescents with sickle cell anaemia treated with hydroxycarbamide: a new tool for uncovering biochemical alterations. Br J Haematol. 2021. PMID: 33476407. doi:10.1111/bjh.17315
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。